A Phase 3b Study for the Treatment of Dystrophic Epidermolysis Bullosa (DEB) in New and Previously EB-101 Treated Patients
Latest Information Update: 04 Jul 2025
At a glance
- Drugs Prademagene zamikeracel (Primary)
- Indications Epidermolysis bullosa dystrophica
- Focus Adverse reactions; Registrational
- Sponsors Abeona therapeutics
Most Recent Events
- 27 Jun 2025 Planned End Date changed from 30 Jun 2025 to 30 Sep 2025.
- 27 Jun 2025 Planned primary completion date changed from 31 Mar 2025 to 30 Sep 2025.
- 27 Jun 2025 Status changed from recruiting to active, no longer recruiting.